» Articles » PMID: 66477

Intrathymic Pathogenesis and Dual Genetic Control of Myasthenia Gravis

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1977 Mar 26
PMID 66477
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

We propose a two-step model for the pathogenesis of myasthenia gravis. In the first step, primitive intrathymic stem-cells are induced by abnormal stimuli to differentiate to (abnormal?) myogenic cells. In the second step, immunocompetent T lymphocytes start an autoimmune reaction against these newly differentiated myogenic cells. The clinical stage is reached when autosensitised effector T lymphocytes leave the thymus and either infiltrate the synaptic spaces of peripheral muscles or participate in the formation of autoantibodies, causing the neuromuscular symptoms. At two points the pathogenesis is under genetic control--the first at the differentiation of the stem-cells to myogenic cells and the second at the immune responsiveness of the lymphocytes to these atypical intrathymic muscle cells.

Citing Articles

The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases.

Zhao K, Sun Y, Zhong S, Luo J Biomark Res. 2024; 12(1):165.

PMID: 39736788 PMC: 11687005. DOI: 10.1186/s40364-024-00711-9.


Thymus and autoimmunity.

Marx A, Yamada Y, Simon-Keller K, Schalke B, Willcox N, Strobel P Semin Immunopathol. 2021; 43(1):45-64.

PMID: 33537838 PMC: 7925479. DOI: 10.1007/s00281-021-00842-3.


Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients.

Leite M, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D Neurology. 2012; 78(20):1601-7.

PMID: 22551731 PMC: 3348852. DOI: 10.1212/WNL.0b013e31825644ff.


Progress in the treatment of myasthenia gravis.

Gold R, Hohlfeld R, Toyka K Ther Adv Neurol Disord. 2010; 1(2):36-51.

PMID: 21180568 PMC: 3002545. DOI: 10.1177/1756285608093888.


Current and future standards in treatment of myasthenia gravis.

Gold R, Schneider-Gold C Neurotherapeutics. 2008; 5(4):535-41.

PMID: 19019304 PMC: 4514693. DOI: 10.1016/j.nurt.2008.08.011.